<code id='9651682A5B'></code><style id='9651682A5B'></style>
    • <acronym id='9651682A5B'></acronym>
      <center id='9651682A5B'><center id='9651682A5B'><tfoot id='9651682A5B'></tfoot></center><abbr id='9651682A5B'><dir id='9651682A5B'><tfoot id='9651682A5B'></tfoot><noframes id='9651682A5B'>

    • <optgroup id='9651682A5B'><strike id='9651682A5B'><sup id='9651682A5B'></sup></strike><code id='9651682A5B'></code></optgroup>
        1. <b id='9651682A5B'><label id='9651682A5B'><select id='9651682A5B'><dt id='9651682A5B'><span id='9651682A5B'></span></dt></select></label></b><u id='9651682A5B'></u>
          <i id='9651682A5B'><strike id='9651682A5B'><tt id='9651682A5B'><pre id='9651682A5B'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:14889
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In